Clinical Cancer Research Prevention Award Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 5243, September 15, 2007. doi: 10.1158/1078-0432.CCR-07-0182
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Talmadge, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Talmadge, J. E.

Molecular Pathways

Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy

James E. Talmadge

Author's Affiliation: Laboratory of Transplantation Immunology, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska

Requests for reprints: James E. Talmadge, University of Nebraska Medical Center, 987660 Nebraska Medical Center, Omaha, NE 68198-7660. Phone: 402-559-5639; Fax: 402-559-4990; E-mail: jtalmadg{at}unmc.edu.

Cancer immunotherapy has focused on inducing and expanding CTLs and improving the immune recognition of weak antigenic determinants expressed by tumors. However, few positive clinical outcomes have been reported due, in part, to tumor-associated immunologic tolerance, supporting the need for an emphasis on overcoming immunosuppression. Systemic immunosuppression is associated with abnormal myelopoiesis secondary to tumor growth, myelosuppressive therapy, and growth factor administration and subsequent expansion/mobilization of bone marrow–derived immunosuppressive cells. These myeloid-derived suppressor cells (MDSC) reduce activated T-cell number and inhibit their function by multiple mechanisms, including depletion of L-arginine by arginase-1 (ARG1) production of nitric oxide, reactive oxygen species, and reactive nitrogen oxide species by inducible nitric oxide synthase. Increased numbers of MDSCs are associated with neoplastic, inflammatory, infectious, and graft-versus-host diseases where they restrain exuberant or novel T-cell responses. In this review, we discuss critical components of MDSC-mediated suppression of T-cell function, including cellular expansion and activation-induced secretion of immunosuppressive mediators. Both components of MDSC bioactivity are amenable to pharmacologic intervention as discussed herein. We also focus on the relationship between MDSCs, tumor growth, therapeutic responses, and the mechanisms of cellular expansion, activation, and immunosuppression.




This article has been cited by other articles:


Home page
J. Immunol.Home page
T. J. Stewart, D. J. Liewehr, S. M. Steinberg, K. M. Greeneltch, and S. I. Abrams
Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells
J. Immunol., July 1, 2009; 183(1): 117 - 128.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. A. Corzo, M. J. Cotter, P. Cheng, F. Cheng, S. Kusmartsev, E. Sotomayor, T. Padhya, T. V. McCaffrey, J. C. McCaffrey, and D. I. Gabrilovich
Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
J. Immunol., May 1, 2009; 182(9): 5693 - 5701.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Zhong, X. Qu, M. Tan, Y. G. Meng, and N. Ferrara
Characterization and Regulation of Bv8 in Human Blood Cells
Clin. Cancer Res., April 15, 2009; 15(8): 2675 - 2684.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J.-I. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
J. Immunol., October 15, 2008; 181(8): 5791 - 5802.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Watanabe, K. Deguchi, R. Zheng, H. Tamai, L.-x. Wang, P. A. Cohen, and S. Shu
Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes
J. Immunol., September 1, 2008; 181(5): 3291 - 3300.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Shojaei and N. Ferrara
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Cancer Res., July 15, 2008; 68(14): 5501 - 5504.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Sawanobori, S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. Shono, M. Kitabatake, K. Kakimi, N. Mukaida, et al.
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice
Blood, June 15, 2008; 111(12): 5457 - 5466.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.